Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies

Current Vascular Pharmacology

Volumn 8, Issue 2, 2010, Pages 220-232

  Bussolati, Benedetta ^a   Deregibus, Maria Chiara ^a   Camussi, Giovanni ^a  

^a Center for Molecular Biotechnology   (Italy)

Author keywords

Angiogenesis; Origin of tumor endothelial cells; Stem cells; Tumor endothelial cells; Vasculogenesis

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; SORAFENIB; SUNITINIB; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR PAX2; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER CELL; CANCER STEM CELL; CELL DEDIFFERENTIATION; CELL FUSION; ENDOTHELIUM CELL; EPIGENETICS; HUMAN; IN VITRO STUDY; MICROARRAY ANALYSIS; PHENOTYPE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ENDOTHELIAL CELL; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77649189072     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110790887036     Document Type: Review

References (112)

1. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res 2004; 117: 3-32.
2. Tepper OM, Capla JM, Galiano RD, et al. Adult vasculogenesis occurs through in situ recruitment, proliferation and tubulization of circulating bone marrow-derived cells. Blood 2005; 105: 1068-77.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
4. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-8.
5. Schiffer D, Bosone I, Dutto A, Di Vito N, Chiò A. The prognostic role of vessel productive changes and vessel density in oligodendroglioma. J Neurooncol 1999; 44: 99-107.
6. Schiffer D, Chiò A, Giordana MT, Mauro A, Migheli A, Vigliani MC. The vascular response to tumor infiltration in malignant gliomas. Morphometric and reconstruction study. Acta Neuropathol 1989; 77: 369-78.
7. Hartmann C, Mueller W, von Deimling A. Pathology and molecular genetics of oligodendroglial tumors. J Mol Med 2004; 82: 638-55.
8. Cassoni P, Gaetano L, Senetta R, Bussolati B, Molinaro L, Bussolati G. Histology far away from Flatland: 3D roller-coasting into grade-dependent angiogenetic patterns in oligodendrogliomas. J Cell Mol Med 2008; 12: 564-8.
9. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity implications for targeted medicine. Curr Opin Chem Biol 2002; 6: 399-404.
10. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002; 8: 121-7.
11. Aird WC. Phenotypic heterogeneity of the endothelium: I. structure, function, and mechanisms. Circ Res 2007; 100: 158 - 73.
12. Ruoslahti E, Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol 2000; 18: 813-27.
13. Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 2002; 8: 563-71.
14. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
15. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 90: 677-84.
16. Harris AL. Hypoxia- a key regulatory factor in tumor growth. Nat Rev Cancer 2002; 2: 38-47.
17. Goh PP, Sze DM, Roufogalis BD. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 2007; 7: 743-58.
18. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-64.
19. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2: 673-82.
20. Mori T, Doi R, Koizumi M, et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 2004; 3: 29-37.
21. Hida K, Hida Y, Amin DN, et al. Tumor- associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64: 8249-55.
22. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of the angiogenic switch concept. Leukemia 2007; 21: 44-52.
23. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-202.
24. Parker BS, Argani P, Cook BP, et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004; 64: 7857-66.
25. Madden SL, Cook BP, Nacht M, et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 2004; 165: 601-8.
26. van Beijnum JR, Dings RP, van der Linden E, et al. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006; 108: 2339-48.
27. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007; 25: 852-61.
28. Lu C, Bonome T, Li Y, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67: 1757-68.
29. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539-54.
30. Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M. Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 2008; 9: 201.
31. Bhati R, Patterson C, Livasy CA, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol 2008; 172: 1381-90.
32. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003; 17: 1159-61.
33. Grange C, Bussolati B, Bruno S, Fonsato V, Sapino A, Camussi G. Isolation and characterization of human breast tumor-derived endothelial cells. Oncol Rep 2006; 15: 381-6.
34. Miebach S, Grau S, Hummel V, Rieckmann P, Tonn JC, Goldbrunner RH. Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades. J Neurooncol 2006; 76: 39-48.
35. Bussolati B, Assenzio B, Deregibus MC, Camussi G. The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med 2006; 84: 852-63.
36. Fonsato V, Buttiglieri S, Deregibus MC, Puntonieri V, Bussolati B, Camussi G. Expression of PAX2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis. Am J Pathol 2006; 168: 706-13.
37. Bussolati B, Grange C, Bruno S, et al. Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp Cell Res 2006; 312: 913-24.
38. Dressler GR, Douglass EC. Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci USA 1992; 89: 1179-83.
39. Amin DN, Hida K, Bielenberg DR, Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006; 66: 2173-80.
40. Duensing S, Munger K. Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability. Oncogene 2002; 21: 6241-8.
41. Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol 2004; 5: 45-54.
42. Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008; 99: 459-66.
43. Gunsilius E, Duba HC, Petzer AL, et al. Evidence from a leukemia model for maintenance of vascular endothelium by bone marrow-derived endothelial cells. Lancet 2000; 355: 1688-91.
44. Streubel B, Chott A, Huber D, et al. Lymphoma-specific aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004; 351: 250-9.
45. Rigolin GM, Fraulini C, Ciccone M, et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006; 107: 2531-5.
46. Mangieri D, Nico B, Benagiano V, De Giorgis M, Vacca A, Ribatti D. Angiogenic activity of multiple myeloma endothelial cells in vivo in the chick embryo chorioallantoic membrane assay is associated to a down-regulation in the expression of endogenous endostatin. J Cell Mol Med 2008; 12: 1023-8.
47. Iwahana M, Utoguchi N, Mayumi T, Goryo M, Okada K. Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors. Anticancer Res 1998; 18: 2977-80.
48. Urbich C, Aicher A, Heeschen C, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005; 39: 733-42.
49. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-8.
50. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bonemarrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7: 1194-201.
51. O'Neill TJ 4th, Wamhoff BR, Owens GK, Skalak TC. Mobilization of bone marrow-derived cells enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells. Circ Res 2005; 97 :1027-35.
52. Ziegelhoeffer T, Fernandez B, Kostin S, et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 2004; 94: 230-8.
53. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105: 3286-94.
54. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211-26.
55. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrowderived endothelial cells to human tumor vasculature. Nat Med 2005; 11: 261-2.
56. Deregibus MC, Cantaluppi V, Calogero R, et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007; 110: 2440-8.
57. Levine SJ. Mechanisms of soluble cytokine receptor generation. J Immunol 2004; 173: 5343-8.
58. Lucas WJ, Yoo BC, Kragler F. RNA as a long-distance information macromolecule in plants. Nat Rev Mol Cell Biol 2001; 2: 849-57.
59. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006; 20: 1487-95.
60. Janowska-Wieczorek A, Majka M, Kijowski J, et al. Plateletderived microparticles bind to hematopoietic progenitor cells and enhance their engraftment. Blood 2001; 98: 3143-9.
61. Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-64.
62. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005; 113: 752-60.
63. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, et al. Tumorderived microvesicles carry several surface determinants and mRNA of tumor cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 2006; 55: 808-18.
64. Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cellderived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006; 20: 847-56.
65. Hood, JL, Pan H, Lanza GM, Wickline SA. Paracrine induction of endothelium by tumor exosomes. Lab Invest 2009; 89: 1317-28.
66. Bergsmedh A, Szeles A, Henriksson M, et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA 2001; 98: 6407-11.
67. Pelham RJ, Rodgers L, Hall I, et al. Identification of alterations in DNA copy number in host stromal cells during tumor progression. Proc Natl Acad Sci USA 2006; 103: 19848-53.
68. Bergsmedh A, Szeles A, Spetz AL, Holmgren L. Loss of the p21(Cip1/Waf1) cyclin kinase inhibitor results in propagation of horizontally transferred DNA. Cancer Res 2002; 62: 575-9.
69. Bruno S, Bussolati B, Grange C, et al. CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 2006; 169: 2223-35.
70. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 5013-21.
71. Bussolati B, Bruno S, Grange C, et al. Isolation of renal progenitor cells from adult human kidney. Am J Pathol 2005; 166: 545-55.
72. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1999; 275: 964-67.
73. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100: 15178-83.
74. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
75. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-5.
76. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007; 445: 106-10.
77. Florek M, Haase M, Marzesco AM, et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005; 319: 15-26.
78. Bissel MJ, LaBarge MA. Context, tissue plasticity and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005; 7: 17-23.
79. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005; 65: 8887-95.
80. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 2002; 62: 3298-307.
81. Duda DG, Fukumura D, Munn LL, et al. Differential transplantability of tumor-associated stromal cells. Cancer Res 2004; 64: 5920-4.
82. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-11.
83. Bussolati B, Grange C, Sapino A, Camussi G. Endothelial cell differentiation of human breast tumor stem/progenitor cells. J Cell Mol Med 2009; 13: 309-19.
84. Reya T, Morrison SJ, Clarcke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
85. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res 2006; 66: 9339-44.
86. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-37.
87. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 2008; 22: 3696-705.
88. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-52.
89. Sapino A, Bongiovanni M, Cassoni P, et al. Expression of CD31 by cells of extensive ductal in situ and invasive carcinoma of the breast. J Pathol 2001; 194: 254-61.
90. Rybak SM, Sanovich E, Hollingshead MG, et al. " Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res 2003; 63: 2812-9.
91. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156: 361-81.
92. Li H, Fan X, Kovi RC, et al. Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. Cancer Res 2007; 67: 10889-98.
93. Pezzolo A, Parodi F, Corrias MV, Cinti R, Gambini C, Pistoia V. Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol 2007; 25: 376-83.
94. Jacobsen BM, Harrel JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB. Spontaneous fusion with and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res 2006; 66: 8274-9.
95. Jain RK. Lessons from multidisciplinary translational trials on antiangiogenic therapy of cancer. Nat Rev Cancer 2008; 8: 309-16.
96. Kesisis G, Broxterman H, Giaccone G. Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des 2007; 13: 2795-809.
97. Khosravi SP, Fernandez PI. Tumoral angiogenesis: Review of the literature. Cancer Invest 2008; 26: 104-8.
98. Nanda A, St Croix B. Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 2004; 16: 44-9.
99. Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): a marker of tumor vasculature and a potential target for therapy. Clin Cancer Res 2008; 14: 1931-7.
100. Bussolati B, Grange C, Tei L, et al. Targeting of human renal tumor-derived endothelial cells with peptides obtained by phage display. J Mol Med 2007; 85: 897-906.
101. Ellerby HM, Arap W, Ellerby LM. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5: 1032-8.
102. Fahr A, Muller K, Nahde T, Muller R, Brusselbach S. A new colloidal lipidic system for gene therapy. J Liposome Res 2002; 12: 37-44.
103. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F] Galacto-RGD identifies the level of integrin alpha(v) beta 3 expression in man. Clin Cancer Res 2006; 12: 3942-9.
104. Geninatti CS, Bussolati B, Tei L, et al. Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res 2006; 66: 9196-201.
105. Dentelli P, Rosso A, Balsamo A, et al. C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium. Blood 2007; 109: 4264-71.
106. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-48.
107. Buttery RC, Rintoul RC, Sethi T. Small cell lung cancer: the importance of the extracellular matrix. Int J Biochem Cell Biol 2004; 36: 1154-60.
108. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRbeta+ perivascular progenitor cells in tumors regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005; 7: 870-9.
109. Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007; 11: 981-1011.
110. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumor biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-80.
111. Martelli AM, Tazzari PL, Tabellini G, et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukaemia cells. Leukaemia 2003; 17: 1794-805.
112. Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 2008; 1784: 150-8.